异动解读 | 和誉-B盘中大涨5.04%，上半年业绩亮眼，花旗看好前景

异动解读

Aug 11

和誉-B（02256）今日盘中大涨5.04%，股价创历史新高，引发市场广泛关注。该公司近期公布的中期业绩表现亮眼，加上分析师的积极评价，推动了股价的上涨。

根据公司最新公布的财报，和誉-B上半年实现收入6.12亿元，同比增长21.5%；归母净利润3.28亿元，同比大增58.8%。中金公司表示，公司业绩超预期，主要得益于默克行权收入超预期。此外，自2025年3月起，公司持续实施股份回购计划，截至上半年末已回购954.5万股，占年初发行股份总数的1.4%，累计投入资金7530万港元，显示出管理层对公司未来发展的信心。

花旗银行近日发布研报，认为和誉-B当前估值偏低。该行指出，公司两款晚期候选药物pimicotinib和irpagratinib具有高度确定性，且差异化创新管线有望实现对外授权。花旗预期irpagratinib在二线肝细胞癌三期临床试验的成功率极高，并认为公司在2025年和2026年将出现多个关键催化剂，包括pimicotinib的上市审批和商业化表现、irpagratinib的三期数据公布，以及ABSK043和ABSK061等多个候选药物的数据更新和潜在的商业合作。基于这些因素，花旗维持"买入"评级，并将目标价从10港元大幅上调至17.5港元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1104721690"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1104721690\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1104721690?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-08-11 15:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104721690","market":"hk","top_or_hot":-1,"title":"异动解读 | 和誉-B盘中大涨5.04%，上半年业绩亮眼，花旗看好前景","media":"异动解读","content":"<p>和誉-B（02256）今日盘中大涨5.04%，股价创历史新高，引发市场广泛关注。该公司近期公布的中期业绩表现亮眼，加上分析师的积极评价，推动了股价的上涨。</p>\n\n<p>根据公司最新公布的财报，和誉-B上半年实现收入6.12亿元，同比增长21.5%；归母净利润3.28亿元，同比大增58.8%。中金公司表示，公司业绩超预期，主要得益于默克行权收入超预期。此外，自2025年3月起，公司持续实施股份回购计划，截至上半年末已回购954.5万股，占年初发行股份总数的1.4%，累计投入资金7530万港元，显示出管理层对公司未来发展的信心。</p>\n\n<p>花旗银行近日发布研报，认为和誉-B当前估值偏低。该行指出，公司两款晚期候选药物pimicotinib和irpagratinib具有高度确定性，且差异化创新管线有望实现对外授权。花旗预期irpagratinib在二线肝细胞癌三期临床试验的成功率极高，并认为公司在2025年和2026年将出现多个关键催化剂，包括pimicotinib的上市审批和商业化表现、irpagratinib的三期数据公布，以及ABSK043和ABSK061等多个候选药物的数据更新和潜在的商业合作。基于这些因素，花旗维持\"买入\"评级，并将目标价从10港元大幅上调至17.5港元。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 和誉-B盘中大涨5.04%，上半年业绩亮眼，花旗看好前景</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 和誉-B盘中大涨5.04%，上半年业绩亮眼，花旗看好前景\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2025-08-11 15:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>和誉-B（02256）今日盘中大涨5.04%，股价创历史新高，引发市场广泛关注。该公司近期公布的中期业绩表现亮眼，加上分析师的积极评价，推动了股价的上涨。</p>\n\n<p>根据公司最新公布的财报，和誉-B上半年实现收入6.12亿元，同比增长21.5%；归母净利润3.28亿元，同比大增58.8%。中金公司表示，公司业绩超预期，主要得益于默克行权收入超预期。此外，自2025年3月起，公司持续实施股份回购计划，截至上半年末已回购954.5万股，占年初发行股份总数的1.4%，累计投入资金7530万港元，显示出管理层对公司未来发展的信心。</p>\n\n<p>花旗银行近日发布研报，认为和誉-B当前估值偏低。该行指出，公司两款晚期候选药物pimicotinib和irpagratinib具有高度确定性，且差异化创新管线有望实现对外授权。花旗预期irpagratinib在二线肝细胞癌三期临床试验的成功率极高，并认为公司在2025年和2026年将出现多个关键催化剂，包括pimicotinib的上市审批和商业化表现、irpagratinib的三期数据公布，以及ABSK043和ABSK061等多个候选药物的数据更新和潜在的商业合作。基于这些因素，花旗维持\"买入\"评级，并将目标价从10港元大幅上调至17.5港元。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02256","symbol_name":"和誉-B","start_time":0,"source_url":"","article_id":"1104721690","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104721690","pubTimestamp":1754897909,"columns":[],"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"和誉-B今日盘中大涨5.04%，股价创历史新高，引发市场广泛关注。该公司近期公布的中期业绩表现亮眼，加上分析师的积极评价，推动了股价的上涨。根据公司最新公布的财报，和誉-B上半年实现收入6.12亿元，同比增长21.5%；归母净利润3.28亿元，同比大增58.8%。花旗银行近日发布研报，认为和誉-B当前估值偏低。该行指出，公司两款晚期候选药物pimicotinib和irpagratinib具有高度确定性，且差异化创新管线有望实现对外授权。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02256":"和誉-B"},"translate_title":"Interpretation of changes | Heyu-B rose 5.04% in intraday trading, with outstanding performance in the first half of the year, Citigroup is optimistic about the prospects","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02256":1},"content_text":"和誉-B（02256）今日盘中大涨5.04%，股价创历史新高，引发市场广泛关注。该公司近期公布的中期业绩表现亮眼，加上分析师的积极评价，推动了股价的上涨。\n根据公司最新公布的财报，和誉-B上半年实现收入6.12亿元，同比增长21.5%；归母净利润3.28亿元，同比大增58.8%。中金公司表示，公司业绩超预期，主要得益于默克行权收入超预期。此外，自2025年3月起，公司持续实施股份回购计划，截至上半年末已回购954.5万股，占年初发行股份总数的1.4%，累计投入资金7530万港元，显示出管理层对公司未来发展的信心。\n花旗银行近日发布研报，认为和誉-B当前估值偏低。该行指出，公司两款晚期候选药物pimicotinib和irpagratinib具有高度确定性，且差异化创新管线有望实现对外授权。花旗预期irpagratinib在二线肝细胞癌三期临床试验的成功率极高，并认为公司在2025年和2026年将出现多个关键催化剂，包括pimicotinib的上市审批和商业化表现、irpagratinib的三期数据公布，以及ABSK043和ABSK061等多个候选药物的数据更新和潜在的商业合作。基于这些因素，花旗维持\"买入\"评级，并将目标价从10港元大幅上调至17.5港元。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}